7.77
[]. Sarosdy MF, et al. Oral bropirimine immunotherapy of bladder carcinoma in situ after prior intravesical bacille Calmette-Guérin. Urology. 998;5():6‐.
[]. Suzuki H, et al. Bropirimine inhibits osteoclast differentiation through production of interferon-β. Biochem Biophys Res Commun. 05;467():46‐5.
[]. Frank G E Perabo, et al. Current and new strategies in immunotherapy for superficial bladder cancer. Urology. 004 Sep;64():409-.
[4]. G Lievano, et al. Bropirimine as neoadjuvant therapy decreases residual disease and expression of markers PCNA and TGF-beta in a rat orthotopic prostate adenocarcinoma. Methods Find Exp Clin Pharmacol. 997 May;9(4):6-7.
[5]. H Akaza, et al. Bropirimine, an orally active anticancer agent for superficial bladder cancer. Eur Urol. 998 Aug;4():07-0.
H6
P80-P405-P50